The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Use of myeloablative Y90-ibritumomab tiuxetan in patients with high-risk CD20+ NHL not eligible for standard ASCT: Five-year results.
L. Devizzi
No relevant relationships to disclose
A. Guidetti
No relevant relationships to disclose
C. Carlo-Stella
No relevant relationships to disclose
C. Tarella
No relevant relationships to disclose
E. Seregni
No relevant relationships to disclose
M. Magni
No relevant relationships to disclose
M. A. Di Nicola
No relevant relationships to disclose
E. Schiavello
No relevant relationships to disclose
P. Matteucci
No relevant relationships to disclose
S. Viviani
No relevant relationships to disclose
E. Bombardieri
No relevant relationships to disclose
A. M. Gianni
No relevant relationships to disclose